# Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

> **NCT02587364** · PHASE1 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 50 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Gemcabene 50 mg
- **DRUG:** Gemcabene 150 mg
- **DRUG:** Gemcabene 450 mg
- **DRUG:** Gemcabene 750/600 mg
- **DRUG:** Gemcabene 900 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02587364
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 1999-09
- **Final completion:** 1999-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587364, "Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02587364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*